MedPath

Merck Sharp & Dohme BV

🇳🇱Netherlands
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

26

Active:26
Completed:0

Trial Phases

1 Phases

Phase 1:19

Drug Approvals

284

CIMA_AEMPS:145
EMA:83
NMPA:55
+1 more agencies

Drug Approvals

Ceftolozane Sulfate and Tazobactam Sodium for Injection

Product Name
注射用头孢洛生他唑巴坦钠
Approval Number
国药准字HJ20250016
Approval Date
Feb 8, 2025
NMPA

Imipenem, Cilastatin Sodium and Relebactam for Injection

Product Name
注射用亚胺西瑞
Approval Number
国药准字HJ20240140
Approval Date
Dec 1, 2024
NMPA

Imipenem, Cilastatin Sodium and Relebactam for Injection

Product Name
注射用亚胺西瑞
Approval Number
国药准字HJ20240141
Approval Date
Dec 1, 2024
NMPA

Ertapenem Sodium for Injection

Product Name
怡万之
Approval Number
国药准字HJ20150481
Approval Date
Nov 29, 2024
NMPA

Ertapenem Sodium for Injection

Product Name
怡万之
Approval Number
国药准字HJ20150480
Approval Date
Nov 29, 2024
NMPA

Aprepitant Capsules

Product Name
意美
Approval Number
国药准字HJ20150377
Approval Date
Mar 20, 2024
NMPA

Aprepitant Capsules

Product Name
意美
Approval Number
国药准字HJ20150380
Approval Date
Mar 20, 2024
NMPA

Aprepitant Capsules

Product Name
意美
Approval Number
国药准字HJ20150378
Approval Date
Mar 20, 2024
NMPA

Aprepitant Capsules

Product Name
意美
Approval Number
国药准字HJ20150379
Approval Date
Mar 20, 2024
NMPA

Aprepitant Capsules

Product Name
意美
Approval Number
国药准字HJ20150381
Approval Date
Mar 20, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials

Phase 1
19 (100.0%)
No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.